Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.

MLA

Van Cangh, P. J., et al. “Free to Total Prostate-Specific Antigen (PSA) Ratio Is Superior to Total-PSA in Differentiating Benign Prostate Hypertrophy from Prostate Cancer.” The Prostate. Supplement, vol. 7, 1996, pp. 30–34. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=8950361&authtype=sso&custid=ns315887.

APA

Van Cangh, P. J., De Nayer, P., Sauvage, P., Tombal, B., Elsen, M., Lorge, F., Opsomer, R., & Wese, F. X. (1996). Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. The Prostate. Supplement, 7, 30–34.

Chicago

Van Cangh, P J, P De Nayer, P Sauvage, B Tombal, M Elsen, F Lorge, R Opsomer, and F X Wese. 1996. “Free to Total Prostate-Specific Antigen (PSA) Ratio Is Superior to Total-PSA in Differentiating Benign Prostate Hypertrophy from Prostate Cancer.” The Prostate. Supplement 7: 30–34. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=8950361&authtype=sso&custid=ns315887.